How India Exports Dasatinib to the World

In the United States, dasatinib is approved under the brand name Sprycel. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for generic versions of dasatinib. For instance, ANDA 203180 for Dasatinib Tablets, 80 mg and 140 mg, was approved for Apotex Corp., indicating the presence of generic competition in the market. The regulatory pathway for dasatinib involves demonstrating bioequivalence to the reference listed drug, Sprycel, and compliance with FDA manufacturing standards. Notably, the substantial number of Indian exporters supplying dasatinib to the U.S. underscores India's significant role in the generic pharmaceutical market.

In the European Union, dasatinib is marketed under the brand name Sprycel, with marketing authorization granted on 20 November 2006. Generic versions, such as Dasatinib Accord, received marketing authorization on 24 March 2022; however, this authorization was withdrawn on 25 March 2023 at the request of the marketing authorization holder, Accord Healthcare S.L.U., due to commercial reasons. The European Medicines Agency (EMA) requires compliance with Good Manufacturing Practice (GMP) standards for all medicinal products, ensuring quality and safety. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the authorization and regulation of pharmaceuticals, adhering to similar stringent standards as the EMA.

Dasatinib is included in the World Health Organization's Model List of Essential Medicines, highlighting its importance in treating leukemia. While specific editions of the list should be consulted for the most current information, its inclusion signifies global recognition of its therapeutic value. Compliance with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), is essential for dasatinib manufacturers to ensure product quality and facilitate international trade.

In India, dasatinib is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), regulates the pricing of essential medicines; however, specific ceiling prices for dasatinib should be verified with the latest NPPA notifications. For export purposes, Indian pharmaceutical companies must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and international standards.

Dasatinib's primary patents have expired, leading to increased generic competition globally. For example, U.S. Patent Number 7,491,725 expired on 28 September 2026, and Patent Number 8,680,103 expired on 4 August 2025. The expiration of these patents has allowed multiple manufacturers to enter the market, increasing accessibility and affordability of dasatinib.

In March 2023, the European Commission withdrew the marketing authorization for Dasatinib Accord at the request of Accord Healthcare S.L.U., citing commercial reasons. This decision reflects the dynamic nature of the pharmaceutical market and the strategic decisions companies make regarding product portfolios.

In January 2026, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the marketing authorization for Iclusig (ponatinib), another tyrosine kinase inhibitor. The new indication includes treatment for adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib, highlighting the evolving treatment landscape for CML.

These developments underscore the importance of staying informed about regulatory changes and market dynamics to navigate the complex pharmaceutical landscape effectively.

India's pharmaceutical industry, including the production of Dasatinib, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 70-80% of India's API and KSM requirements are sourced from China, creating a significant dependency on Chinese suppliers. This reliance exposes the supply chain to risks associated with geopolitical tensions, trade disputes, and regulatory changes in China.

Recent disruptions have highlighted the vulnerabilities in this dependency. For instance, in March 2026, the closure of the Strait of Hormuz due to escalating conflicts led to significant delays and increased costs in the transportation of raw materials. This event underscored the fragility of supply chains reliant on specific geographic routes and suppliers.

The export data for Dasatinib from India reveals a high supplier concentration, with the top five exporters accounting for 78.5% of the total export value. SUN PHARMACEUTICAL INDUSTRIES LIMITED leads with an 18.5% share, followed closely by DR. REDDY'S LABORATORIES LTD at 18.5%, MSN LABORATORIES PRIVATE LIMITED at 16.2%, EUGIA PHARMA SPECIALITIES LIMITED at 13.3%, and SUN PHARMACEUTICAL INDUSTRIES LTD at 12.0%. This concentration indicates a significant single-source risk, where disruptions affecting these key players could have a substantial impact on the global supply of Dasatinib.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at reducing import dependence on critical pharmaceutical ingredients. In November 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and 6-APA, which are crucial for antibiotic production. While these initiatives are steps toward self-reliance, their impact on reducing dependency for drugs like Dasatinib remains to be seen.

Geopolitical tensions have significantly impacted global supply chains. The closure of the Strait of Hormuz in March 2026 disrupted the transit of essential goods, including pharmaceuticals, leading to increased shipping costs and delays. This event affected approximately 20% of the world's daily oil supply and had cascading effects on various industries.

Additionally, tensions in the Red Sea and the Strait of Hormuz have raised concerns about the security of maritime routes critical for the transportation of pharmaceutical products. These disruptions have led to increased freight and insurance costs, further straining the supply chain.

• Diversify Supplier Base: Engage with a broader range of API and KSM suppliers across different geographies to reduce dependency on a single country or region.

• Enhance Domestic Production: Invest in domestic manufacturing capabilities for critical APIs and KSMs to build a more resilient supply chain.

• Develop Alternative Shipping Routes: Identify and establish alternative logistics and shipping routes to mitigate risks associated with geopolitical disruptions.

• Strengthen Inventory Management: Maintain strategic stockpiles of essential raw materials and finished products to buffer against supply chain interruptions.

• Monitor Geopolitical Developments: Implement a robust monitoring system to stay informed about geopolitical events that could impact supply chains, enabling proactive risk management.

RISK_LEVEL: HIGH